1140 related articles for article (PubMed ID: 35444647)
1. Molnupiravir and Its Antiviral Activity Against COVID-19.
Tian L; Pang Z; Li M; Lou F; An X; Zhu S; Song L; Tong Y; Fan H; Fan J
Front Immunol; 2022; 13():855496. PubMed ID: 35444647
[TBL] [Abstract][Full Text] [Related]
2. New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses.
Siniavin AE; Gushchin VA; Shastina NS; Darnotuk ES; Luyksaar SI; Russu LI; Inshakova AM; Shidlovskaya EV; Vasina DV; Kuznetsova NA; Savina DM; Zorkov ID; Dolzhikova IV; Sheremet AB; Logunov DY; Zigangirova NA; Gintsburg AL
Antiviral Res; 2024 May; 225():105871. PubMed ID: 38555022
[TBL] [Abstract][Full Text] [Related]
3. Molnupiravir: A lethal mutagenic drug against rapidly mutating severe acute respiratory syndrome coronavirus 2-A narrative review.
Masyeni S; Iqhrammullah M; Frediansyah A; Nainu F; Tallei T; Emran TB; Ophinni Y; Dhama K; Harapan H
J Med Virol; 2022 Jul; 94(7):3006-3016. PubMed ID: 35315098
[TBL] [Abstract][Full Text] [Related]
4. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity.
Yip AJW; Low ZY; Chow VTK; Lal SK
Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815
[TBL] [Abstract][Full Text] [Related]
5. Molnupiravir for the treatment of COVID-19.
Santani BG; LeBlanc BW; Thakare RP
Drugs Today (Barc); 2022 Jul; 58(7):335-350. PubMed ID: 35851869
[TBL] [Abstract][Full Text] [Related]
6. Antiviral Efficacy of Molnupiravir for COVID-19 Treatment.
Bai Y; Shen M; Zhang L
Viruses; 2022 Apr; 14(4):. PubMed ID: 35458493
[TBL] [Abstract][Full Text] [Related]
7. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sheahan TP; Sims AC; Zhou S; Graham RL; Pruijssers AJ; Agostini ML; Leist SR; Schäfer A; Dinnon KH; Stevens LJ; Chappell JD; Lu X; Hughes TM; George AS; Hill CS; Montgomery SA; Brown AJ; Bluemling GR; Natchus MG; Saindane M; Kolykhalov AA; Painter G; Harcourt J; Tamin A; Thornburg NJ; Swanstrom R; Denison MR; Baric RS
Sci Transl Med; 2020 Apr; 12(541):. PubMed ID: 32253226
[TBL] [Abstract][Full Text] [Related]
8. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M
J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive review on molnupiravir in COVID-19: a novel promising antiviral to combat the pandemic.
Khiali S; Khani E; B Rouy S; Entezari-Maleki T
Future Microbiol; 2022 Mar; 17(5):377-391. PubMed ID: 35199608
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of ß-d-N4-Hydroxycytidine, the Parent Nucleoside of Prodrug Molnupiravir, in Nonplasma Compartments of Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
FitzGerald R; Dickinson L; Else L; Fletcher T; Hale C; Amara A; Walker L; Penchala SD; Lyon R; Shaw V; Greenhalf W; Bullock K; Lavelle-Langham L; Reynolds H; Painter W; Holman W; Ewings S; Griffiths G; Khoo S
Clin Infect Dis; 2022 Aug; 75(1):e525-e528. PubMed ID: 35271729
[TBL] [Abstract][Full Text] [Related]
11. Molnupiravir: an antiviral drug against COVID-19.
Dave B; Shah KC; Chorawala MR; Shah N; Patel P; Patel S; Shah P
Arch Virol; 2023 Sep; 168(10):252. PubMed ID: 37710056
[TBL] [Abstract][Full Text] [Related]
12. Small-Molecule Antiviral β-d-
Agostini ML; Pruijssers AJ; Chappell JD; Gribble J; Lu X; Andres EL; Bluemling GR; Lockwood MA; Sheahan TP; Sims AC; Natchus MG; Saindane M; Kolykhalov AA; Painter GR; Baric RS; Denison MR
J Virol; 2019 Dec; 93(24):. PubMed ID: 31578288
[TBL] [Abstract][Full Text] [Related]
13. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
14. Molnupiravir: First Approval.
Syed YY
Drugs; 2022 Mar; 82(4):455-460. PubMed ID: 35184266
[TBL] [Abstract][Full Text] [Related]
15. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir.
Waters MD; Warren S; Hughes C; Lewis P; Zhang F
Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215
[TBL] [Abstract][Full Text] [Related]
16. Decoding molnupiravir-induced mutagenesis in SARS-CoV-2.
Menéndez-Arias L
J Biol Chem; 2021 Jul; 297(1):100867. PubMed ID: 34118236
[TBL] [Abstract][Full Text] [Related]
17. Interaction and antiviral treatment of coinfection between SARS-CoV-2 and influenza in vitro.
Liu D; Leung KY; Lam HY; Zhang R; Fan Y; Xie X; Chan KH; Hung IF
Virus Res; 2024 Jul; 345():199371. PubMed ID: 38621598
[TBL] [Abstract][Full Text] [Related]
18. Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19.
Imran M; Kumar Arora M; Asdaq SMB; Khan SA; Alaqel SI; Alshammari MK; Alshehri MM; Alshrari AS; Mateq Ali A; Al-Shammeri AM; Alhazmi BD; Harshan AA; Alam MT; Abida
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641339
[TBL] [Abstract][Full Text] [Related]
19. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19.
Painter GR; Natchus MG; Cohen O; Holman W; Painter WP
Curr Opin Virol; 2021 Oct; 50():17-22. PubMed ID: 34271264
[TBL] [Abstract][Full Text] [Related]
20. Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro.
Jonsdottir HR; Siegrist D; Julien T; Padey B; Bouveret M; Terrier O; Pizzorno A; Huang S; Samby K; Wells TNC; Boda B; Rosa-Calatrava M; Engler OB; Constant S
Biomed Pharmacother; 2022 Jun; 150():113058. PubMed ID: 35658229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
